

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3298.1001-000APPLICATION NO.
10/072,611INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

March 22, 2004

(See several sheets if necessary)

FIRST NAMED INVENTOR
Brian Leyland-JonesFILING DATE
February 8, 2002EXAMINER
C.J. CheuCONFIRMATION NO.
1456GROUP
1641

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,830,672	11-03-1998	Wainer <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	AL	WO 00/55624 A2	09-21-2000	Brian Leyland-Jones		
	AM	EP 0921396 A2	06-09-1999	Pfizer Products Inc.		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Tang, B.K., <i>et al.</i> , "Caffeine as a Metabolic Probe: Validation of its Use for Acetylator Phenotyping," <i>Clinical Pharmacology & Therapeutics</i> , 49(6): 648-657 (1991).
AS	Kroemer, H.K. and Eichelbaum, M., "It's the Genes, Stupid". Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism," <i>Life Sciences</i> , 56(26): 2285-2298 (1995).
AT	Wong, P., <i>et al.</i> , "A Competitive Enzyme Linked Immunosorbent Assay for the Determination of <i>N</i> -acetyltransferase (NAT2) Phenotypes," <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 13(9): 1079-1086 (1995).
AU	Wong, P., <i>et al.</i> , "Syntheses of Caffeine Metabolites Derivatives for Measuring CYP1A2 Activity by ELISA," Proceedings of the 90th Annual Meeting of the American Association for Cancer Research, 40:53 (1999).
AV	Wolf, C.R. and Smith, G., "Chapter 18. Cytochrome P450 CYP2D6," <i>Metabolic Polymorphisms and Susceptibility to Cancer</i> , 148:209-229 (1999).

EXAMINER

DATE CONSIDERED

6/3/2004